drugset / Trial / NCT06674694
The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.
RandomizedParallel-groupOpen-labelTreatment
Summary
Study to evaluate the safety and tolerability of single ascending doses of brexpiprazole long-acting injection in healthy subjects/patients with schizophrenia.
Timeline
- Start
- 2024-04-10
- Primary completion
- 2026-06-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brexpiprazole | Small molecule | 20 mg | — |
| Subject | Brexpiprazole | Small molecule | 40 mg | — |
| Subject | Brexpiprazole | Small molecule | 80 mg | — |
| Subject | Brexpiprazole | Small molecule | 160 mg | — |
| Subject | Brexpiprazole | Small molecule | 240 mg | — |
| Subject | Brexpiprazole | Small molecule | 320 mg | — |